Deficient DNA repair of triple helix-directed double psoralen damage in human cells  by Sandor, Zoltan & Bredberg, Anders
FEBS 16204 FEBS Letters 374 (1995) 287 291 
Deficient DNA repair of triple helix-directed ouble psoralen damage in 
human cells 
Zoltan Sandor*, Anders Bredberg 
Department of Medical Microbiology, University of Lund, General Hospital, S-205 02 Malm6, Sweden 
Received 17 July 1995; revised version received 21 September 1995 
Abstract Damage induced by a single psoralen-modified triple 
helix-forming oligonucleotide has been reported to be efficiently 
repaired in human cells. In this study we investigated a set of 
psoralen coupled oligonucleotides introducing multiple lesions 
into the target DNA. A simian virus 40 (SV40) shuttle vector was 
in vitro treated with different triple helix-forming oligonucleo- 
tides and UVA radiation, leading to double psoralen adducts at 
the supF mutational target gene of the plasmid. After passage in 
the Raji human cell line the recovered vector was analysed in an 
indicator bacterial strain. The results show that double psoralen 
adducts, located at both ends of a long triple helix, cannot be 
repaired efficiently in human cells. 
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1. Introduction 
Triple helix formation between a double-helical DNA and a 
single-stranded oligonucleotide is a novel approach to specifi- 
cally inhibit the biological function of the target DNA [1,2]. 
Two levels where the inhibition can be performed are the dou- 
ble-helical structural and the base coded informational level of 
the DNA. 
In antigene strategy the double helical structure of the target 
is altered by triplex formation, preventing various proteins 
from working on the target DNA [3-6]. With a simple unmod- 
ified triplex-forming oligonucleotide, the inhibition of gene 
function is inherently transient, due to the reversible nature of 
the binding of the oligonucleotide to the DNA. In vitro perma- 
nent repression can be achieved by covalent modification of the 
target duplex, e.g. crosslinking of the two strands of the DNA 
by triple helix-directed psoralen [7]. However, in vivo the cellu- 
lar DNA repair process has been shown to be able to overcome 
this inhibition [8]. Therefore, oligonucleotides capable of form- 
ing repair-resistant DNA damage would be useful in antigene 
strategy. 
To inhibit the function of the DNA on the coded informa- 
tional level the nucleotide sequence of the target has to be 
modified. Although psoralen-modified triple helix-forming ol- 
igonucleotides have been used for targeted mutagenesis [9,10], 
the mutagenesis process has been inefficient, in the sense that 
only a small fraction of the psoralen damage can be converted 
into mutations [11]. Therefore, there is a great demand for triple 
helix directed mutagens capable of inducing damage that is 
more efficiently transformed into mutations. 
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With either of these two levels of inhibition, the normal 
cellular repair of triple helix-directed amage needs to be dis- 
turbed for an efficient inactivation of the target o be achieved. 
Consequently, we have tried to devise psoralen-modified ol- 
igonucleotides capable of inducing more complex types of dam- 
age. Here we report that DNA damage induced by oligonucle- 
otides forming long triplex regions with double psoralen mod- 
ifications cannot be repaired efficiently in human cells. 
2. Materials and methods 
2.1. Plasmid and oligonuch, otides 
pSP2Tx (Fig. l) is a derivate of the SV40-based shuttle vector pSPTx 
[11]. The plasmid contains the early transcription unit of SV40 which 
allows replication i  human cells. The mutational target amber suppres- 
sor tRNA gene supF is placed between the bacterial replication origin 
and the fl-lactamase gene. During the construction of pSP2Tx another 
11 bp long purine rich region was placed immediately after the triple 
helix target site of pSPTx, providing a second triplex forming region. 
Triplex-forming oligonucleotides (TFOs) were obtained from Appli- 
gene (Illkirch Cedex, France). TFO1 is a previously described [11], 
22-mer guanine rich triple helix-forming oligonucleotide with psoralen 
linked to the 5' end through a hexamethylene linker (Fig. 1). TFO2 is 
a 33-mer with a 5' end psoralen modification similar to TFO1. TFO3 
is an 11-mer oligonucleotide with a psoralen group attached to the 3' 
end via a CgHI702N linker [12]. TFO4 denotes the simultaneous e of 
TFO1 and TFO3. TFO5 is a 33-mer guanine rich oligonucleotide with 
psoralen groups at both ends. 
2.2. Triple helix and psoralen adduct formation 
For triple helix formation the target DNA was incubated in the 
presence of TFO in a 10 mM Tris-HC1, pH 7.4, 20 mM MgCI2 buffer 
at 37°C for 1 h. For covalent psoralen adduct formation the samples 
were kept in a microtiter plate on ice and irradiated with 0.8 mW/cm 2
UVA of a hand held long-wave UV lamp. For detection of psoralen 
adduct formation a 180 bp long EcoRI-SacI fragment of the supF gene 
was labelled by Klenow polymerase and [c~-35S]dATP atthe EcoRI site 
and purified from ~in agarose gel. -5  ng of the fragment was incubated 
with 10 pmol TFO in 5/ll buffer and UVA-irradiated as described. 
2/ll was run on a denaturing polyacrylamide g l and autoradiographed. 
Radioactivity corresponding to autoradiogram bands was determined 
in gel slices by an LKB-Wallac 1209 liquid scintillation counter. 
2.3. Cell transfection and mutant analysis 
5/tg plasmid pSP2Tx was incubated with 150 pmol TFO in 30/11 
buffer, UVA-irradiated for 32 min and electroporated into Raji human 
B lymphoblast cells. The cells were grown for 48 h to allow for repair 
and replication of the plasmid, then the cells were harvested, low molec- 
ular weight DNA was prepared, unreplicated vectors were eliminated 
by DpnI digestion and the sample was transformed into the MBM7070 
E. coli indicator strain by electroporation. Mutants were counted and 
their plasmid DNA was sequenced [11]. 
3. Results 
3.1. Design of  triplex-fi)rming psoralen-modified 
oligonucleotides 
Previously, we investigated the repair and mutagenic proper- 
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Fig. h Schematic presentation of the structures of the triple helix- 
forming oligonucleotides and plasmid pSP2Tx. The target sequence of
the tRNA gene is detailed and triplex regions I and II are indicated. 
Black triangles mark the estimated repair patch of TFO1 -directed am- 
age. SV40 = simian virus 40 T antigen and replication origin; 
amp r= ampicillin resistance gene; ori = replication origin of pBR327; 
supF = suppressor tRNA coding sequence; pro = transcription pro- 
moter; ter = transcription terminator; sig = signature sequence. 
ties of a 22-mer triplex-forming psoralen-modified oligonucleo- 
tide (TFO 1) which could target psoralen adducts to the thymine 
residues 166-167 of the supF gene of plasmid pSPTx [11]. We 
could observe induction of base changes mainly at position 167, 
but most of the damage was repaired correctly. 
Since triple helix formation is known to prevent binding of 
proteins to and modification of the target DNA [1,2], it was 
somewhat surprising to observe an efficient repair of triplex 
psoralen adducts. The human excision repair complex is known 
to cut the DNA strand at the 4th-5th phosphodiester bond in 
3' direction and the 5' 22nd-24th phosphodiester bond around 
a psoralen adduct, and to remove the damaged region as a 
26 29 bp long oligonucleotide [13]. To explain the correct re- 
moval of TFOl-directed psoralen damage it can be assumed 
that the 22 bp long triplex region fits within the 26-29 bp 
excision repair patch and therefore does not interfere with the 
repair process. 
To obtain triplex-directed psoralen damage which cannot be 
repaired, we tried to devise oligonucleotides which might inter- 
fere with the correct excision repair. Therefore, we inserted a
11 bp purine run (forming triplex site I1) in plasmid pSP2Tx 
immediately after the first triplex site (Fig. 1). In this plasmid 
TFO1 can bind to triplex site I and upon UVA irradiation 
direct psoralen adduct formation to position 166-167. The 33- 
mer triplex forming oligonucleotide called TFO2 with 5'-psor- 
alen modification can direct psoralen adducts to the same site 
as TFO1, but the longer triplex region might block the normal 
excision repair. The ll-mer oligonucleotide with 3'-psoralen 
modification (TFO3) can bind to triplex site II and direct psor- 
alen damage to the thymine residues at position 199-200. This 
oligonucleotide applied together with TFO1 (this mixture is 
called TFO4) may give a 33 bp long triplex region with psoralen 
damage at both ends. Finally, the 33-mer oligonucleotide with 
psoralen groups at both ends (TFO5) was devised which can 
bind to both triplex sites and therefore can direct psoralen 
damage to both positions 166167 and 199-200. Binding of 
TFOs to the expected target sites was confirmed by a DNase 
I footprint assay (data not shown). 
3.2. Analysis of triplex-directed psoralen adduct Jormation 
A labelled 180 bp fragment of the supF gene was incubated 
with TFOs, UVA-irradiated and analysed on a denaturing gel 
(Fig. 2). 
In the control sample without TFO only one band can be 
seen corresponding to the labelled purine-rich strand of the 
target. With TFO1 and 2 min UVA dose a strong second slowly 
migrating band appears indicating psoralen monoadduct for- 
mation. At 32 min UVA a third band at the top of the gel 
indicates psoralen crosslink formation between the two strands 
of the target sequence. Quantitation of psoralen adduct forma- 
tion showed that with TFO1 plus 32 min UVA approximately 
20% of the target molecules have an interstrand crosslink, 60% 
have a monoadduct on the purine-rich strand, 15% have a 
monoadduct on the pyrimidine-rich strand and 5% of the target 
molecules are unmodified (results not shown). These data are 
similar to the data we previously obtained with the pSPTx 
plasmid and TFO1 [11]. 
Similar results were obtained with TFO2. Here the band 
containing monoadducts appears above the corresponding 
band of TFO1, since the attached oligonucleotide is 11 bp 
longer. Quantitation showed 20% with crosslink, 55% with 
monoadduct on the purine rich strand, 15% with monoadduct 
on the pyrimidine-rich strand and 10% of the target to be 
unmodified. This result shows that psoralen adduct formation 
is somewhat affected by the length of the triplex-forming ol- 
igonucleotide. 
In the sample treated with the relatively short TFO3 both the 
monoadduct and the crosslink bands migrate faster than the 
corresponding TFO1 bands. In the 32 min UVA irradiated 
sample 80% crosslink, 5% purine-rich strand monoadduct, 5% 
pyrimidine-rich strand monoadduct and 10% unmodified plas- 
mid were seen. This means that triplex-directed psoralen adduct 
formation at position 199 200 is different from that at position 
166-167. Crosslink formation ismore efficient and both strands 
of the target react similarly. These variations can be due to the 
oligo 
UVA (min 
t---- .~ ID  
I - ' -  
Fig. 2. Detection of triplex-directed psoralen adduct formation in the 
supF gene fragment. On the top of the gel the applied TFOs and the 
time of the UVA-irradiation are indicated. The structure of the reaction 
products in some bands are shown on the left side. Lane 1 = control 
sample without TFO, but with UVA radiation, lanes 2-11 = samples 
treated with different TFOs plus a low and a high dose of UVA radia- 
tion. 
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facts that TFO3 targets a 5'TpA3' sequence, instead of a 
5'APT3' sequence like TFO1 and TFO2, and that the psoralens 
are coupled differently to the oligonucleotides. 
With two psoralen molecules directed against he target (in 
the cases of TFO4 and TFO5) 16 different reaction products 
can be expected. On a gel all these products cannot be distin- 
guished, since some of them migrate similarly. However, the 
analysis indicates that with TFO4, 75% of the plasmids con- 
tained at least one crosslink, 1% is unmodified, and the rest 
(24%) contain at least one monoadduct. 
When TFO5 was applied, 86% crosslinked vector (including 
when the two psoralens reacted as monoadducts on the oppo- 
site strands of the plasmid), 13% vector with at least one 
monoadduct and 1% unmodified vector was obtained. These 
results how that psoralen adducts can be simultaneously and 
efficiently formed at both ends of a triple helix region. 
3.3. Analysis of shuttle vector recoveredJrom cell transfections 
Shuttle vector pSP2Tx was treated with different TFOs and 
UVA radiation and then transfected into Raji cells. Two days 
later the plasmid was recovered and transformed into E. coli 
indicator bacteria nd mutant white colonies were scored. The 
results are presented in Table 1. 
The control samples (no treatment, TFO1 alone, UVA alone) 
gave 0.05-0.08% mutation frequencies, imilar to those seen 
previously with the pSPTx vector [11]. The plasmid survival of 
the TFO1 (without UVA) treated sample was chosen as 100%, 
since the presence of a high concentration f oligonucleotide 
in the sample can have some effect on the efficiency of transfec- 
tion [14]. 
The sample treated with TFO1 gave a 0.91% mutation fre- 
quency which is somewhat lower than the 1.3% observed by us 
previously [1 l]. This difference can originate from the varia- 
tions in cell type (Raji or Jurkat) or vector (in the case of 
pSP2Tx we have less crosslinks, and some of the frequent mu- 
tations give lightblue colonies and may therefore be able to 
escape detection). The plasmid survival decreased to 75%, but 
this value is within the range of the experimental variability. 
With TFO2 we got 0.82% mutants which is very similar to 
the value we obtained with TFO1, and the survival is 118% 
indicating no plasmid elimination. These data show that TFO2 
is well-repaired and has no more mutagenic effect than TFO1. 
Interestingly, TFO3 caused a high (0.75%) mutation fre- 
quency and a reduction of the survival (55%) although it directs 
the psoralen adducts outside the supF gene. A part of this high 
Table 1 
Effect of TFO treatments on mutation frequency and plasmid survival 
Type of Mutants/ Mutation Plasmid 
treatment ~ scored colonies frequency (%) survival (%)b 
No treatment 12/18400 0.07 (123) 
UVA 9/17800 0.05 (139) 
TFO1 11/14100 0.08 100 
TFO1 + UVA 172/18900 0.91 75 
TFO2 + UVA 176/21400 0.82 118 
TFO3 + UVA 138/18400 0.75 55 
TFO4 + UVA 480/16800 2.86 14 
TFO5 + UVA 316/19100 1.65 10 
a UVA stands for 32 min UVA irradiation. 
b Based on number of colonies among corresponding aliquots of plated 
bacteria. 
value can be explained by the fact that TFO3 treatment can 
induce deletions (results hown below) reaching into the end of 
the tRNA gene and in some cases also into essential parts of 
the plasmid. 
When both TFO1 and TFO3 were used together the muta- 
tion frequency was raised to 2.86%. Even more striking, the 
very low (14%) plasmid survival indicates that the triplex-di- 
rected double psoralen damage results in plasmid elimination. 
With TFO5 we obtained a lower (1.65%) mutation frequency. 
The plasmid survival data was only 10%, reflecting that TFO5- 
directed psoralen damage are poorly repaired, too. 
3.4. Analysis of mutant plasmids 
Plasmid DNA of 15 mutants from transfections with each 
of the TFOs + UVA was sequenced. The data are presented in 
Fig. 3. 
The mutations from the TFOl-treated samples were mainly 
T--~A and T~G transversions targeted to position 167. We 
could find one mutant with a 79 bp deletion, too. This pattern 
is the same as that previously observed with TFO1 and the 
pSPTx plasmid [11]. TFO2 mutants howed essentially the 
same picture indicating that a longer triple helix region down- 
stream of the psoralen adduct site does not alter the mutation 
pattern. 
The most frequent mutation type in the case of TFO3 treat- 
ment presumably is a non-detectable ase substitution outside 
the supF region (at position 199-200). As expected, the pattern 
shows no mutations at position 167, but some deletions involv- 
ing the end of the tRNA gene. Some mutations can be observed 
throughout the two triplex forming regions which can either 
originate from the repair of the TFO3-directed psoralen dam- 
age or be of spontaneous origin. 
Mutants from sample treated with TFO4 and TFO5 show a 
very similar pattern compared to TFO1 treatment. This proba- 
bly reflects the fact that plasmids with double psoralen damage 
become eliminated and do not induce detectable mutations, 
leaving the relatively few plasmids having adducts only at posi- 
tion 166 167 bp to be responsible for the observed mutations. 
This also means that the unreacted psoralen group at the 3' end 
of TFO5 does not alter the mutagenesis process. 
4. Discussion 
Upon 32 min UVA-irradiation TFO1 and TFO2 introduced 
psoralen damage into the great majority of the target molecules. 
However, this heavy load of damage induced no more than 
0.91% and 0.82% mutants, respectively, and only a slight de- 
crease in plasmid survival. This is in good agreement with 
previous observations of efficient repair of TFOl-directed 
psoralen damage [11] and indicates that the longer TFO2 tri- 
plex region downstream of the psoralen damage site has no 
negative ffect on the repair process. 
TFO3 treatment of the vector caused a decreased (55%) 
survival indicating that this type of damage is not repaired as 
efficiently as those of TFO1 and TFO2. Unfortunately, it is 
difficult to evaluate the mutation data of TFO3, since the ad- 
ducts are located outside the supF gene and some of the muta- 
tions therefore probably remain undetected. 
Each of TFO4 and TFO5 can form a continuous 33 bp long 
triplex region with covalent psoralen damage at both ends. 
Upon 32 min UVA-irradiation ~81% of the plasmids have psor- 
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Fig. 3. Distribution of mutations in the supF gene region after TFO treatments. Mutations obtained with different TFOs are indicated separately 
under the wild type sequence. 'X' indicates one base pair deletion, T means one base pair insertion. Multiple mutations in one plasmid are underlined. 
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alen adduct formation at both ends of the triplex, -18% have 
psoralen damage at one end and-  1% is unmodified. After trans- 
fection we observed a higher (2.86% and 1.65%) mutation fre- 
quency and a very low (14% and 10%) plasmid survival. This 
low survival shows that most of the plasmids are eliminated and 
indicates that the cells are not able to repair the double psoralen 
damage. The mutation pattern resembles the TFO1 and TFO2 
mutation patterns, suggesting that the mutations are induced 
when only the position 166-167 psoralen has reacted. These 
data also mean that the relative mutation frequency per sur- 
vival is higher, whereas the absolute number of mutants per 
transfection is lower compared to the TFO1 and TFO2 treated 
samples. 
These data indicate that plasmids having psoralen adducts 
at both ends of a long triplex region are not repaired in human 
cells, but eliminated. This result is in good agreement with 
observations howing that vicinal lesions are particularly 
problematic in DNA repair [15,16]. Unfortunately, we could 
not get information about he exact mechanism of this elimina- 
tion. There are at least two possible explanations. The first 
explanation is that the damage is not repaired at all, therefore 
the plasmid cannot replicate and the DpnI digestion removes 
it. Another explanation is that some kind of misrepair occurs 
resulting in long deletions. In our plasmid the supF gene is 
situated between two essential parts of the vector (the ampicillin 
resistance gene and the bacterial replication origin), therefore, 
plasmids having long (>250 bp) deletions inactivating one of 
these regions are not viable in bacteria. 
Currently, there is some ambiguity in the literature as to 
whether triplex-forming oligonucleotide-directed single psor- 
alen damage is repaired or not in mammalian cells. One group 
reported efficient repair in 48 h [8], while others observed no 
repair during 72 h (M.W. Van Dyke, personal communica- 
tions). In our case, while damage from TFOI and TFO2 seems 
to be repaired efficiently, the decreased survival observed with 
TFO3 indicates that some of the TFO3-directed damage is not 
repaired. Probably slight differences, e.g. in the sequence con- 
text around the damage, in the exact structure of the psoralen 
adducts and in the length and orientation of the triplex region 
will determine the efficiency of the repair process. 
In conclusion, our results how that triplex-targeted double 
psoralen damage is unrepairable, ven in the case when the 
corresponding triplex-directed single psoralen adducts are effi- 
ciently repaired. 
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